What is the P/E ratio of Adimmune 2025?
The Adimmune P/E ratio is -447.39.
Access the world's leading financial data and tools
Subscribe for $2 
Overview
Profile
Adimmune stock stock price, forecast, news, chart, split, dividend and analysis Adimmune ariva, Adimmune onvista, Adimmune finanzen.net, Adimmune aktienfinder, Adimmune marketscreener, Adimmune marketwatch, Adimmune bloomberg, Adimmune handelsblatt, Adimmune wiwo, Adimmune forum
4142.TW
TW0004142005
Price
Price
23.25
Today +/-
+0.01
Today %
+0.86 %
Ticker4142.TW
ISINTW0004142005
Adimmune stock price
%
Weekly
Details
Price
ⓘOverview
The Quote Chart provides detailed and dynamic insights into the Adimmune stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.
Intraday Feature
The intraday feature provides real-time data, allowing investors to view the Adimmune stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.
Total Return and Relative Price Change
View the total return of the Adimmune stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.
Interpretation and Investment
Utilize the comprehensive data presented in the Quote Chart to analyze Adimmune's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.
Adimmune Stock Price History
| Date | Adimmune Price |
|---|---|
| 3/6/2025 | 23.25 undefined |
| 3/5/2025 | 23.05 undefined |
| 3/4/2025 | 23.05 undefined |
| 3/3/2025 | 23.30 undefined |
| 2/27/2025 | 23.75 undefined |
| 2/26/2025 | 23.55 undefined |
| 2/25/2025 | 24.00 undefined |
| 2/24/2025 | 24.55 undefined |
| 2/21/2025 | 23.60 undefined |
| 2/20/2025 | 23.25 undefined |
| 2/19/2025 | 23.40 undefined |
| 2/18/2025 | 23.65 undefined |
| 2/17/2025 | 23.65 undefined |
| 2/14/2025 | 23.90 undefined |
| 2/13/2025 | 24.10 undefined |
| 2/12/2025 | 23.60 undefined |
| 2/11/2025 | 23.95 undefined |
| 2/10/2025 | 24.15 undefined |
| 2/7/2025 | 25.05 undefined |
| 2/6/2025 | 24.90 undefined |
Adimmune Revenue, EBIT, Net Income TW0004142005 ·
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Adimmune, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Adimmune from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Adimmune’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Adimmune. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Adimmune’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Adimmune’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Adimmune’s growth potential.
Adimmune Revenue, EBIT and net profit per share
| Date | Adimmune Revenue | Adimmune EBIT | Adimmune Net Income |
|---|---|---|---|
| 2026e | 1.81 B undefined | 41.82 M undefined | -17.52 M undefined |
| 2025e | 1.74 B undefined | 32.64 M undefined | -21.91 M undefined |
| 2024e | 1.73 B undefined | -76.5 M undefined | -105.14 M undefined |
| 2023 | 1.79 B undefined | -722.75 M undefined | -639.89 M undefined |
| 2022 | 2.25 B undefined | 93.57 M undefined | 290.98 M undefined |
| 2021 | 1.79 B undefined | -54.09 M undefined | 43.07 M undefined |
| 2020 | 1.87 B undefined | -25.81 M undefined | 1.24 B undefined |
| 2019 | 1.3 B undefined | -298.98 M undefined | -280.68 M undefined |
| 2018 | 822.37 M undefined | -725.21 M undefined | -617.84 M undefined |
| 2017 | 562.74 M undefined | -705.22 M undefined | -760.18 M undefined |
| 2016 | 606.73 M undefined | -591.87 M undefined | -595.35 M undefined |
| 2015 | 290.74 M undefined | -737.53 M undefined | -761.09 M undefined |
| 2014 | 480.51 M undefined | -647.6 M undefined | -614.42 M undefined |
| 2013 | 414.1 M undefined | -646.5 M undefined | -600.5 M undefined |
| 2012 | 387.2 M undefined | -666.7 M undefined | -603.9 M undefined |
| 2011 | 290.4 M undefined | -581.1 M undefined | -471.3 M undefined |
| 2010 | 834.8 M undefined | 220.8 M undefined | 161.3 M undefined |
| 2009 | 1.37 B undefined | 740.6 M undefined | 588.9 M undefined |
| 2008 | 182.3 M undefined | -84.5 M undefined | -29.8 M undefined |
| 2007 | 223.5 M undefined | -36.5 M undefined | -34.3 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2007 | 223.5 M TWD | -36.5 M TWD | -34.3 M TWD |
| 2008 | 182.3 M TWD | -84.5 M TWD | -29.8 M TWD |
| 2009 | 1.37 B TWD | 740.6 M TWD | 588.9 M TWD |
| 2010 | 834.8 M TWD | 220.8 M TWD | 161.3 M TWD |
| 2011 | 290.4 M TWD | -581.1 M TWD | -471.3 M TWD |
| 2012 | 387.2 M TWD | -666.7 M TWD | -603.9 M TWD |
| 2013 | 414.1 M TWD | -646.5 M TWD | -600.5 M TWD |
| 2014 | 480.51 M TWD | -647.6 M TWD | -614.42 M TWD |
| 2015 | 290.74 M TWD | -737.53 M TWD | -761.09 M TWD |
| 2016 | 606.73 M TWD | -591.87 M TWD | -595.35 M TWD |
| 2017 | 562.74 M TWD | -705.22 M TWD | -760.18 M TWD |
| 2018 | 822.37 M TWD | -725.21 M TWD | -617.84 M TWD |
| 2019 | 1.3 B TWD | -298.98 M TWD | -280.68 M TWD |
| 2020 | 1.87 B TWD | -25.81 M TWD | 1.24 B TWD |
| 2021 | 1.79 B TWD | -54.09 M TWD | 43.07 M TWD |
| 2022 | 2.25 B TWD | 93.57 M TWD | 290.98 M TWD |
| 2023 | 1.79 B TWD | -722.75 M TWD | -639.89 M TWD |
| 2024e | 1.73 B TWD | -76.5 M TWD | -105.14 M TWD |
| 2025e | 1.74 B TWD | 32.64 M TWD | -21.91 M TWD |
| 2026e | 1.81 B TWD | 41.82 M TWD | -17.52 M TWD |
Adimmune Income Statement, Balance Sheet, Cash Flow Statement
Simple
Expanded
Income Statement
Balance Sheet
Cashflow
| 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.22 | 0.18 | 1.37 | 0.83 | 0.29 | 0.39 | 0.41 | 0.48 | 0.29 | 0.61 | 0.56 | 0.82 | 1.3 | 1.87 | 1.79 | 2.25 | 1.79 | 1.73 | 1.74 | 1.81 |
| - | -18.39 | 652.20 | -39.08 | -65.23 | 33.45 | 6.98 | 15.94 | -39.58 | 108.97 | -7.26 | 46.26 | 58.03 | 43.88 | -4.07 | 25.54 | -20.70 | -3.31 | 0.98 | 3.90 |
| 33.18 | 17.58 | 74.87 | 64.27 | -78.97 | -98.19 | -59.66 | -42.71 | -100.00 | -31.02 | -46.44 | -35.77 | 12.86 | 33.33 | 34.36 | 39.58 | 22.97 | 23.75 | 23.52 | 22.64 |
| 0.07 | 0.03 | 1.03 | 0.54 | -0.23 | -0.38 | -0.25 | -0.21 | -0.29 | -0.19 | -0.26 | -0.29 | 0.17 | 0.62 | 0.62 | 0.89 | 0.41 | 0 | 0 | 0 |
| -0.03 | -0.03 | 0.59 | 0.16 | -0.47 | -0.6 | -0.6 | -0.61 | -0.76 | -0.6 | -0.76 | -0.62 | -0.28 | 1.24 | 0.04 | 0.29 | -0.64 | -0.11 | -0.02 | -0.02 |
| - | -14.71 | -2,127.59 | -72.62 | -392.55 | 28.03 | -0.50 | 2.33 | 23.94 | -21.81 | 27.73 | -18.82 | -54.62 | -543.21 | -96.54 | 574.42 | -320.34 | -83.57 | -80.00 | -19.05 |
| 173.7 | 173.7 | 173.7 | 170.9 | 174.3 | 188.7 | 196.1 | 214.82 | 249.66 | 248.7 | 249.54 | 250.36 | 310.39 | 410.04 | 429.6 | 427.68 | 421.51 | 0 | 0 | 0 |
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Details
Keystats
ⓘRevenue and Growth
The Adimmune Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.
Gross Margin
The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.
EBIT and EBIT Margin
EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.
Income and Growth
Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.
Shares Outstanding
Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.
Interpreting Year to Year Comparison
Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.
Expectations and Predictions
Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Adimmune is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.
Adimmune stock margins TW0004142005 ·
The Adimmune margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Adimmune. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Adimmune.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Adimmune's sales revenue. A higher gross margin percentage indicates that the Adimmune retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Adimmune's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Adimmune's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Adimmune's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Adimmune. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Adimmune's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Adimmune Margin History
| Adimmune Gross margin | Adimmune Profit margin | Adimmune EBIT margin | Adimmune Profit margin |
|---|---|---|---|
| 2026e | 23.02 % | 2.31 % | -0.97 % |
| 2025e | 23.02 % | 1.87 % | -1.26 % |
| 2024e | 23.02 % | -4.43 % | -6.09 % |
| 2023 | 23.02 % | -40.49 % | -35.85 % |
| 2022 | 39.58 % | 4.16 % | 12.92 % |
| 2021 | 34.39 % | -3.02 % | 2.4 % |
| 2020 | 33.33 % | -1.38 % | 66.41 % |
| 2019 | 12.89 % | -23 % | -21.6 % |
| 2018 | -35.79 % | -88.19 % | -75.13 % |
| 2017 | -46.42 % | -125.32 % | -135.08 % |
| 2016 | -31.09 % | -97.55 % | -98.13 % |
| 2015 | -99.89 % | -253.67 % | -261.78 % |
| 2014 | -42.7 % | -134.78 % | -127.87 % |
| 2013 | -59.74 % | -156.12 % | -145.01 % |
| 2012 | -98.27 % | -172.18 % | -155.97 % |
| 2011 | -78.99 % | -200.1 % | -162.29 % |
| 2010 | 64.25 % | 26.45 % | 19.32 % |
| 2009 | 74.84 % | 54.06 % | 42.99 % |
| 2008 | 17.83 % | -46.35 % | -16.35 % |
| 2007 | 33.24 % | -16.33 % | -15.35 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2007 | 33.24 % | -16.33 % | -15.35 % |
| 2008 | 17.83 % | -46.35 % | -16.35 % |
| 2009 | 74.84 % | 54.06 % | 42.99 % |
| 2010 | 64.25 % | 26.45 % | 19.32 % |
| 2011 | -78.99 % | -200.1 % | -162.29 % |
| 2012 | -98.27 % | -172.18 % | -155.97 % |
| 2013 | -59.74 % | -156.12 % | -145.01 % |
| 2014 | -42.7 % | -134.78 % | -127.87 % |
| 2015 | -99.89 % | -253.67 % | -261.78 % |
| 2016 | -31.09 % | -97.55 % | -98.13 % |
| 2017 | -46.42 % | -125.32 % | -135.08 % |
| 2018 | -35.79 % | -88.19 % | -75.13 % |
| 2019 | 12.89 % | -23 % | -21.6 % |
| 2020 | 33.33 % | -1.38 % | 66.41 % |
| 2021 | 34.39 % | -3.02 % | 2.4 % |
| 2022 | 39.58 % | 4.16 % | 12.92 % |
| 2023 | 23.02 % | -40.49 % | -35.85 % |
| 2024e | 23.02 % | -4.43 % | -6.09 % |
| 2025e | 23.02 % | 1.87 % | -1.26 % |
| 2026e | 23.02 % | 2.31 % | -0.97 % |
Adimmune Stock Sales Revenue, EBIT, Earnings per Share TW0004142005 ·
The Adimmune earnings per share therefore indicates how much revenue Adimmune has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
3 years
5 years
10 years
25 Years
Max
Sales per Share
EBIT per share
Earnings per Share
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Adimmune earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Adimmune's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Adimmune’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adimmune's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Adimmune Revenue, EBIT and net profit per share
| Date | Adimmune Sales per Share | Adimmune EBIT per share | Adimmune Earnings per Share |
|---|---|---|---|
| 2026e | 4.22 undefined | 0 undefined | -0.04 undefined |
| 2025e | 4.06 undefined | 0 undefined | -0.05 undefined |
| 2024e | 4.02 undefined | 0 undefined | -0.24 undefined |
| 2023 | 4.24 undefined | -1.71 undefined | -1.52 undefined |
| 2022 | 5.26 undefined | 0.22 undefined | 0.68 undefined |
| 2021 | 4.18 undefined | -0.13 undefined | 0.1 undefined |
| 2020 | 4.56 undefined | -0.06 undefined | 3.03 undefined |
| 2019 | 4.19 undefined | -0.96 undefined | -0.9 undefined |
| 2018 | 3.28 undefined | -2.9 undefined | -2.47 undefined |
| 2017 | 2.26 undefined | -2.83 undefined | -3.05 undefined |
| 2016 | 2.44 undefined | -2.38 undefined | -2.39 undefined |
| 2015 | 1.16 undefined | -2.95 undefined | -3.05 undefined |
| 2014 | 2.24 undefined | -3.01 undefined | -2.86 undefined |
| 2013 | 2.11 undefined | -3.3 undefined | -3.06 undefined |
| 2012 | 2.05 undefined | -3.53 undefined | -3.2 undefined |
| 2011 | 1.67 undefined | -3.33 undefined | -2.7 undefined |
| 2010 | 4.88 undefined | 1.29 undefined | 0.94 undefined |
| 2009 | 7.89 undefined | 4.26 undefined | 3.39 undefined |
| 2008 | 1.05 undefined | -0.49 undefined | -0.17 undefined |
| 2007 | 1.29 undefined | -0.21 undefined | -0.2 undefined |
| Sales per Share | EBIT per share | Earnings per Share | |
|---|---|---|---|
| 2007 | 1.29 TWD | -0.21 TWD | -0.2 TWD |
| 2008 | 1.05 TWD | -0.49 TWD | -0.17 TWD |
| 2009 | 7.89 TWD | 4.26 TWD | 3.39 TWD |
| 2010 | 4.88 TWD | 1.29 TWD | 0.94 TWD |
| 2011 | 1.67 TWD | -3.33 TWD | -2.7 TWD |
| 2012 | 2.05 TWD | -3.53 TWD | -3.2 TWD |
| 2013 | 2.11 TWD | -3.3 TWD | -3.06 TWD |
| 2014 | 2.24 TWD | -3.01 TWD | -2.86 TWD |
| 2015 | 1.16 TWD | -2.95 TWD | -3.05 TWD |
| 2016 | 2.44 TWD | -2.38 TWD | -2.39 TWD |
| 2017 | 2.26 TWD | -2.83 TWD | -3.05 TWD |
| 2018 | 3.28 TWD | -2.9 TWD | -2.47 TWD |
| 2019 | 4.19 TWD | -0.96 TWD | -0.9 TWD |
| 2020 | 4.56 TWD | -0.06 TWD | 3.03 TWD |
| 2021 | 4.18 TWD | -0.13 TWD | 0.1 TWD |
| 2022 | 5.26 TWD | 0.22 TWD | 0.68 TWD |
| 2023 | 4.24 TWD | -1.71 TWD | -1.52 TWD |
| 2024e | 4.02 TWD | 0 TWD | -0.24 TWD |
| 2025e | 4.06 TWD | 0 TWD | -0.05 TWD |
| 2026e | 4.22 TWD | 0 TWD | -0.04 TWD |
Adimmune business model
Adimmune is one of the most popular companies on Eulerpool.com.
Adimmune Eulerpool Fair Value
Details
Fair Value
ⓘUnderstanding Fair Value
The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.
Income-Based Fair Value
This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.
Example 2022
Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)
Revenue-Based Fair Value
It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.
Example 2022
Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)
Dividend-Based Fair Value
This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.
Example 2022
Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)
Expectations and Forecasts
Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.
Comparative Analysis
Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.
Adimmune historical P/E ratio, EBIT multiple, and P/S ratio
Adimmune shares outstanding TW0004142005 ·
The number of shares was Adimmune in 2024 — This indicates how many shares 421.508 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
3 years
5 years
10 years
25 Years
Max
Number of stocks
Details
Revenue, EBIT and Earnings per share
ⓘRevenue Per Share
Revenue per share represents the total revenue Adimmune earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT Per Share
EBIT per share indicates Adimmune's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income Per Share
Income per share, or earnings per share (EPS), reveals the portion of Adimmune’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected Values
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Adimmune's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
| Number of stocks | |
|---|---|
| 2007 | 173.7 M Aktien |
| 2008 | 173.7 M Aktien |
| 2009 | 173.7 M Aktien |
| 2010 | 170.9 M Aktien |
| 2011 | 174.3 M Aktien |
| 2012 | 188.7 M Aktien |
| 2013 | 196.1 M Aktien |
| 2014 | 214.82 M Aktien |
| 2015 | 249.66 M Aktien |
| 2016 | 248.7 M Aktien |
| 2017 | 249.54 M Aktien |
| 2018 | 250.36 M Aktien |
| 2019 | 310.39 M Aktien |
| 2020 | 410.04 M Aktien |
| 2021 | 429.6 M Aktien |
| 2022 | 427.68 M Aktien |
| 2023 | 421.51 M Aktien |
| 2024e | 421.51 M Aktien |
| 2025e | 421.51 M Aktien |
| 2026e | 421.51 M Aktien |
Adimmune dividend history and estimates TW0004142005 ·
In 2024, Adimmune paid a dividend amounting to 0 TWD. Dividend means that Adimmune distributes a portion of its profits to its owners.
3 years
5 years
10 years
25 Years
Max
Dividend
Dividend (Estimate)
Details
Dividend
ⓘDividend Overview
The dividend per year chart for Adimmune provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.
Interpretation and Use
A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Adimmune’s potential for long-term investment and income generation through dividends.
Investment Strategy
Incorporate the dividend data in evaluating Adimmune's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.
Adimmune Dividend History
| Date | Adimmune Dividend |
|---|---|
| 2026e | -0.2 undefined |
| 2025e | -0.25 undefined |
| 2024e | -1.22 undefined |
| 2021 | 0.5 undefined |
| Dividend | Dividend (Estimate) | |
|---|---|---|
| 2007 | 0 TWD | 0 TWD |
| 2008 | 0 TWD | 0 TWD |
| 2009 | 0 TWD | 0 TWD |
| 2010 | 0 TWD | 0 TWD |
| 2011 | 0 TWD | 0 TWD |
| 2012 | 0 TWD | 0 TWD |
| 2013 | 0 TWD | 0 TWD |
| 2014 | 0 TWD | 0 TWD |
| 2015 | 0 TWD | 0 TWD |
| 2016 | 0 TWD | 0 TWD |
| 2017 | 0 TWD | 0 TWD |
| 2018 | 0 TWD | 0 TWD |
| 2019 | 0 TWD | 0 TWD |
| 2020 | 0 TWD | 0 TWD |
| 2021 | 0.5 TWD | 0 TWD |
| 2022 | 0 TWD | 0 TWD |
| 2023 | 0 TWD | 0 TWD |
| 2024e | 0 TWD | -1.22 TWD |
| 2025e | 0 TWD | -0.25 TWD |
| 2026e | 0 TWD | -0.2 TWD |
Adimmune dividend payout ratio TW0004142005 ·
In 2024, Adimmune had a payout ratio of 498.5%. The payout ratio indicates the percentage of the company's profits that Adimmune distributes as dividends.
3 years
5 years
10 years
25 Years
Max
Payout ratio
Details
Payout ratio
ⓘWhat is Yearly Payout Ratio?
The yearly payout ratio for Adimmune represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.
How to Interpret the Data
A lower payout ratio for Adimmune could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.
Using the Data for Investments
Evaluate Adimmune's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.
Adimmune Payout Ratio History
| Date | Adimmune Payout ratio |
|---|---|
| 2026e | 498.5 % |
| 2025e | 498.5 % |
| 2024e | 498.5 % |
| 2023 | 498.5 % |
| 2022 | 498.5 % |
| 2021 | 498.5 % |
| 2020 | 498.5 % |
| 2019 | 498.5 % |
| 2018 | 498.5 % |
| 2017 | 498.5 % |
| 2016 | 498.5 % |
| 2015 | 498.5 % |
| 2014 | 498.5 % |
| 2013 | 498.5 % |
| 2012 | 498.5 % |
| 2011 | 498.5 % |
| 2010 | 498.5 % |
| 2009 | 498.5 % |
| 2008 | 498.5 % |
| 2007 | 498.5 % |
| Payout ratio | |
|---|---|
| 2007 | 498.5 % |
| 2008 | 498.5 % |
| 2009 | 498.5 % |
| 2010 | 498.5 % |
| 2011 | 498.5 % |
| 2012 | 498.5 % |
| 2013 | 498.5 % |
| 2014 | 498.5 % |
| 2015 | 498.5 % |
| 2016 | 498.5 % |
| 2017 | 498.5 % |
| 2018 | 498.5 % |
| 2019 | 498.5 % |
| 2020 | 498.5 % |
| 2021 | 498.5 % |
| 2022 | 498.5 % |
| 2023 | 498.5 % |
| 2024e | 498.5 % |
| 2025e | 498.5 % |
| 2026e | 498.5 % |
Unfortunately, there are currently no price targets and forecasts available for Adimmune.
Adimmune latest earnings and earnings surprises
| Date | EPS Estimate | EPS Actual | Quarterly report |
|---|---|---|---|
| 9/30/2023 | 0.68 | 0.62 (-9.28 %) | 2023 Q3 |
| 6/30/2023 | -0.09 | -0.57 (-538.3 %) | 2023 Q2 |
| 3/31/2023 | -0.58 | -0.59 (-1.24 %) | 2023 Q1 |
| 12/31/2022 | 0.28 | 0.14 (-49.78 %) | 2022 Q4 |
| 9/30/2022 | 0.48 | 0.98 (104.42 %) | 2022 Q3 |
| 6/30/2022 | 0.09 | 0.11 (26.87 %) | 2022 Q2 |
| 3/31/2022 | -0.45 | -0.55 (-23.4 %) | 2022 Q1 |
| 12/31/2021 | 0.16 | 0.69 (322.79 %) | 2021 Q4 |
| 9/30/2021 | 0.26 | 0.37 (45.1 %) | 2021 Q3 |
| 6/30/2021 | -0.63 | -0.38 (39.91 %) | 2021 Q2 |
1
2
3
4
Adimmune shareholders
% | Name | Stocks | Change | Date |
|---|---|---|---|---|
| 11.31149 % | National Development Fund, Executive Yuan | 48,584,000 | 0 | 10/31/2024 |
| 4.82853 % | Yu Cheng Management Consultant Company Ltd. | 20,739,000 | 0 | 10/31/2024 |
| 3.92959 % | Yao Hwa Glass Co Ltd | 16,878,000 | 0 | 10/31/2024 |
| 2.56647 % | The Vanguard Group, Inc. | 11,023,228 | 0 | 1/31/2025 |
| 2.12172 % | Lin (Jian Hong) | 9,113,000 | 0 | 10/31/2024 |
| 1.92731 % | Center Laboratories Inc | 8,278,000 | 0 | 10/31/2024 |
| 0.87099 % | YuChuan Culture Limited Partnership | 3,741,000 | 0 | 10/31/2024 |
| 0.81605 % | Chan (Chi-Hsien) | 3,505,000 | 0 | 10/31/2024 |
| 0.81488 % | Lin (Min Xiong) | 3,500,000 | 0 | 10/31/2024 |
| 0.81488 % | Lan (A Wen) | 3,500,000 | 0 | 10/31/2024 |
1
2
3
4
Adimmune Executives and Management Board
Mr. Chi-Shean Chan
Adimmune Chairman of the Board, Chief Executive Officer (since 2008)
Compensation 134.6 M
Mr. Chung-Cheng Liu
Adimmune General Manager, Director (since 2012)
Compensation 9.26 M
Mr. Chin-Chuan Chang
Adimmune Chief Operating Officer (since 2019)
Compensation 5.74 M
Mr. Fei Pan
Adimmune Deputy General Manager, Chief Legal Officer
Compensation 5.25 M
Mr. Chun-Cheng Chen
Adimmune Chief Medical Officer
Compensation 4.87 M
1
2
3
4
Most common questions regarding Adimmune
What is the P/S ratio of Adimmune 2025?
The Adimmune P/S ratio is 5.62.
What is the Quality Investing of Adimmune?
The Quality Investing for Adimmune is 3/10.
What is the revenue of Adimmune 2025?
The expected Adimmune revenue is 1.74 B TWD.
How high is the profit of Adimmune 2025?
The expected Adimmune profit is -21.91 M TWD.
What is the business model of Adimmune
No history available for Adimmune.
What is the Adimmune dividend?
Adimmune pays a dividend of 0 TWD distributed over payouts per year.
How often does Adimmune pay dividends?
The dividend cannot currently be calculated for Adimmune or the company does not pay out a dividend.
What is the Adimmune ISIN?
The ISIN of Adimmune is TW0004142005.
What is the Adimmune ticker?
The ticker of Adimmune is 4142.TW.
How much dividend does Adimmune pay?
Over the past 12 months, Adimmune paid a dividend of 0.5 TWD . This corresponds to a dividend yield of about 2.15 %. For the coming 12 months, Adimmune is expected to pay a dividend of -0.2 TWD.
What is the dividend yield of Adimmune?
The current dividend yield of Adimmune is 2.15 %.
When does Adimmune pay dividends?
Adimmune pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Adimmune?
Adimmune paid dividends every year for the past 0 years.
What is the dividend of Adimmune?
For the upcoming 12 months, dividends amounting to -0.2 TWD are expected. This corresponds to a dividend yield of -0.87 %.
In which sector is Adimmune located?
Adimmune is assigned to the 'Health' sector.
Wann musste ich die Aktien von Adimmune kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Adimmune from 10/13/2021 amounting to 0.5 TWD, you needed to have the stock in your portfolio before the ex-date on 9/14/2021.
When did Adimmune pay the last dividend?
The last dividend was paid out on 10/13/2021.
What was the dividend of Adimmune in the year 2024?
In the year 2024, Adimmune distributed 0 TWD as dividends.
In which currency does Adimmune pay out the dividend?
The dividends of Adimmune are distributed in TWD.
Adimmune stock
Sector
Health
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website Adimmune
Country
Taiwan, Province of China 🇹🇼
Currency
TWD
Initial public offering
Sep 29, 2010
GOSIN
Global Open Securities Identification Number
Cusip
Y0013X105
Market capitalization
Quality Investing
3 / 10Details
PEG
0.34
P/E ratio
Forward P/E ratio
-93.21
P/S ratio
Forward P/S ratio
5.68
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
Adimmune Peer Group
Adimmune Eulerpool News
Adimmune News
Adimmune Ticker
| Stock Exchange | Adimmune Ticker |
|---|---|
| TAI | 4142.TW |
Adimmune FIGI
| Adimmune Ticker | Adimmune FIGI |
|---|---|
| 4142:TT (Taiwan Stock Exchange) | BBG001636XY8 |
All fundamentals about Adimmune
Our stock analysis for Adimmune Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adimmune Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
